BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29853306)

  • 1. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
    Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
    Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
    Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
    Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
    Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
    Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
    J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
    Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
    Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
    Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
    Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.
    Greenland NY; Zhang L; Cowan JE; Carroll PR; Stohr BA; Simko JP
    J Urol; 2019 Jul; 202(1):90-95. PubMed ID: 30810466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
    J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    Nyame YA; Grimberg DC; Greene DJ; Gupta K; Kartha GK; Berglund R; Gong M; Stephenson AJ; Magi-Galluzzi C; Klein EA
    J Urol; 2018 Feb; 199(2):438-444. PubMed ID: 28941920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
    Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
    JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.